| Spread | 1.32 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.006402% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.005927% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 141.09 |
| Open* | 141.49 |
| 1-Year Change* | -11.01% |
| Day's Range* | 140.48 - 143.69 |
| 52 wk Range | 117.08-188.99 |
| Average Volume (10 days) | 809.60K |
| Average Volume (3 months) | 19.56M |
| Market Cap | 34.59B |
| P/E Ratio | 3.21 |
| Shares Outstanding | 242.52M |
| Revenue | 20.22B |
| EPS | 44.44 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 27, 2023 | 142.59 | 1.13 | 0.80% | 141.46 | 143.82 | 140.03 |
| Jan 26, 2023 | 141.09 | -1.98 | -1.38% | 143.07 | 143.84 | 140.37 |
| Jan 25, 2023 | 142.22 | -0.87 | -0.61% | 143.09 | 144.55 | 140.99 |
| Jan 24, 2023 | 143.27 | 0.08 | 0.06% | 143.19 | 144.16 | 140.65 |
| Jan 23, 2023 | 143.73 | 0.95 | 0.67% | 142.78 | 144.84 | 141.38 |
| Jan 20, 2023 | 142.49 | 1.65 | 1.17% | 140.84 | 143.35 | 138.99 |
| Jan 19, 2023 | 140.39 | -2.69 | -1.88% | 143.08 | 143.94 | 139.57 |
| Jan 18, 2023 | 142.94 | -0.98 | -0.68% | 143.92 | 147.66 | 142.74 |
| Jan 17, 2023 | 144.32 | -0.11 | -0.08% | 144.43 | 145.61 | 140.88 |
| Jan 13, 2023 | 144.49 | -5.59 | -3.72% | 150.08 | 151.01 | 141.99 |
| Jan 12, 2023 | 149.04 | 0.05 | 0.03% | 148.99 | 150.56 | 146.19 |
| Jan 11, 2023 | 148.99 | -5.98 | -3.86% | 154.97 | 155.85 | 146.75 |
| Jan 10, 2023 | 153.29 | 4.35 | 2.92% | 148.94 | 154.16 | 147.14 |
| Jan 9, 2023 | 148.56 | -1.93 | -1.28% | 150.49 | 152.89 | 148.56 |
| Jan 6, 2023 | 149.59 | 4.39 | 3.02% | 145.20 | 155.90 | 144.53 |
| Jan 5, 2023 | 145.18 | -0.73 | -0.50% | 145.91 | 147.59 | 143.59 |
| Jan 4, 2023 | 145.99 | -3.61 | -2.41% | 149.60 | 151.83 | 145.72 |
| Jan 3, 2023 | 147.99 | -2.66 | -1.77% | 150.65 | 154.92 | 147.99 |
| Dec 30, 2022 | 151.03 | -1.78 | -1.16% | 152.81 | 153.91 | 145.89 |
| Dec 29, 2022 | 153.24 | 1.25 | 0.82% | 151.99 | 156.01 | 151.99 |
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Total revenue | 61.598 | 127.575 | 108.589 | 482.325 | 18976.7 |
| Revenue | 61.598 | 127.575 | 108.589 | 482.325 | 18976.7 |
| Cost of Revenue, Total | 9.318 | 13.69 | 17.361 | 59.333 | 2911.5 |
| Gross Profit | 52.28 | 113.885 | 91.228 | 422.992 | 16065.2 |
| Total Operating Expense | 122.875 | 181.429 | 290.107 | 564.742 | 3692.9 |
| Selling/General/Admin. Expenses, Total | 29.493 | 27.07 | 44.45 | 103.457 | 328.9 |
| Research & Development | 75.637 | 124.728 | 197.893 | 614.837 | 916.3 |
| Depreciation / Amortization | 10.489 | 20.617 | 32.388 | 35.296 | 40.2 |
| Unusual Expense (Income) | 0.281 | 0 | -137.2 | ||
| Other Operating Expenses, Total | -2.343 | -4.676 | -1.985 | -248.181 | -1.1 |
| Operating Income | -61.277 | -53.854 | -181.518 | -82.417 | 15283.8 |
| Interest Income (Expense), Net Non-Operating | -24.575 | 6.24 | 2.404 | -60.337 | -215.5 |
| Other, Net | -0.053 | -0.048 | -0.326 | -3.048 | -21.9 |
| Net Income Before Taxes | -85.905 | -47.662 | -179.44 | -145.802 | 15046.4 |
| Net Income After Taxes | -85.95 | -48.262 | -179.172 | 15.198 | 10292.5 |
| Minority Interest | 0.297 | 0.243 | 0.116 | 0 | |
| Net Income Before Extra. Items | -85.653 | -48.019 | -179.056 | 15.198 | 10292.5 |
| Net Income | -85.653 | -48.019 | -179.056 | 15.198 | 10292.5 |
| Income Available to Common Excl. Extra. Items | -85.653 | -48.019 | -179.056 | 15.198 | 10292.5 |
| Income Available to Common Incl. Extra. Items | -85.653 | -48.019 | -179.056 | 15.198 | 10292.5 |
| Diluted Net Income | -85.653 | -48.019 | -179.056 | 15.198 | 10292.5 |
| Diluted Weighted Average Shares | 226.262 | 226.262 | 210.654 | 253.3 | 259.7 |
| Diluted EPS Excluding Extraordinary Items | -0.37856 | -0.21223 | -0.85 | 0.06 | 39.6323 |
| Diluted Normalized EPS | -0.37775 | -0.21223 | -0.85 | 0.06 | 39.2709 |
| Interest Expense (Income) - Net Operating | -365.7 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 2048.4 | 5308.5 | 6087.3 | 5532.5 | 6374.6 |
| Revenue | 2048.4 | 5308.5 | 6087.3 | 5532.5 | 6374.6 |
| Cost of Revenue, Total | 233.1 | 883.8 | 1211.4 | 583.2 | 1294.1 |
| Gross Profit | 1815.3 | 4424.7 | 4875.9 | 4949.3 | 5080.5 |
| Total Operating Expense | 386.2 | 1110.1 | 1363.8 | 832.8 | 1621.9 |
| Selling/General/Admin. Expenses, Total | 47.6 | 59.8 | 76.9 | 145.9 | 105.1 |
| Research & Development | 208.7 | 194 | 251.9 | 261.7 | 275 |
| Depreciation / Amortization | 7.5 | 8.4 | 10.3 | 12.7 | 10.8 |
| Interest Expense (Income) - Net Operating | -40.7 | -34.4 | -165.4 | -125.2 | -126.8 |
| Unusual Expense (Income) | -67.9 | -0.1 | -20.9 | -48.3 | 0 |
| Other Operating Expenses, Total | -2.1 | -1.4 | -0.4 | 2.8 | 63.7 |
| Operating Income | 1662.2 | 4198.4 | 4723.5 | 4699.7 | 4752.7 |
| Interest Income (Expense), Net Non-Operating | -17.4 | -170.9 | -55.7 | 28.5 | 268 |
| Other, Net | -2.5 | -4.7 | -0.4 | -14.3 | -2.6 |
| Net Income Before Taxes | 1642.3 | 4022.8 | 4667.4 | 4713.9 | 5018.1 |
| Net Income After Taxes | 1128.1 | 2787.2 | 3211 | 3166.2 | 3698.8 |
| Net Income Before Extra. Items | 1128.1 | 2787.2 | 3211 | 3166.2 | 3698.8 |
| Net Income | 1128.1 | 2787.2 | 3211 | 3166.2 | 3698.8 |
| Income Available to Common Excl. Extra. Items | 1128.1 | 2787.2 | 3211 | 3166.2 | 3698.8 |
| Income Available to Common Incl. Extra. Items | 1128.1 | 2787.2 | 3211 | 3166.2 | 3698.8 |
| Diluted Net Income | 1128.1 | 2787.2 | 3211 | 3166.2 | 3698.8 |
| Diluted Weighted Average Shares | 243.125 | 244.063 | 260 | 260.253 | 243.125 |
| Diluted EPS Excluding Extraordinary Items | 4.64 | 11.42 | 12.35 | 12.1658 | 15.2136 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 4.44816 | 11.4197 | 12.2947 | 12.0412 | 15.2136 |
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 189.637 | 448.961 | 560.151 | 1666.9 | 15072.3 |
| Cash and Short Term Investments | 172.352 | 411.831 | 520.829 | 1347.44 | 2074.3 |
| Cash | 172.106 | 411.495 | 519.149 | 1210.21 | 1692.7 |
| Short Term Investments | 0.246 | 0.336 | 1.68 | 137.234 | 381.6 |
| Total Receivables, Net | 9.094 | 28.44 | 20.205 | 170.521 | 12382.1 |
| Accounts Receivable - Trade, Net | 4.575 | 18.938 | 11.913 | 165.468 | 12381.7 |
| Total Inventory | 3.876 | 5.789 | 11.722 | 64.12 | 502.5 |
| Prepaid Expenses | 0.815 | 0.155 | 0.351 | 29.845 | |
| Other Current Assets, Total | 3.5 | 2.746 | 7.044 | 54.967 | 113.4 |
| Total Assets | 374.713 | 652.986 | 797.647 | 2318.62 | 15830.8 |
| Property/Plant/Equipment, Total - Net | 101.522 | 115.965 | 148.062 | 325.956 | 520.4 |
| Property/Plant/Equipment, Total - Gross | 129.225 | 152.617 | 197.345 | 384.288 | 594.6 |
| Accumulated Depreciation, Total | -27.703 | -36.652 | -49.285 | -58.332 | -74.2 |
| Goodwill, Net | 0.534 | 0.534 | 2.978 | 53.697 | 57.8 |
| Intangibles, Net | 83.003 | 87.508 | 86.456 | 109.793 | 144.6 |
| Long Term Investments | 0.019 | 0.018 | 0 | 21.3 | |
| Other Long Term Assets, Total | -0.002 | 0 | 162.278 | 14.4 | |
| Total Current Liabilities | 158.544 | 126.121 | 138.142 | 606.014 | 3481.6 |
| Accounts Payable | 52.538 | 41.721 | 20.498 | 102.288 | 160 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.832 | 8.266 | 3.485 | 6.127 | 129.9 |
| Other Current Liabilities, Total | 104.174 | 76.134 | 114.159 | 497.599 | 3191.7 |
| Total Liabilities | 424.009 | 386.833 | 304.155 | 946.774 | 3937.1 |
| Total Long Term Debt | 0 | 5.6 | 68.904 | 231.047 | 171.6 |
| Long Term Debt | 0 | 5.6 | 14.777 | 153.016 | 17.9 |
| Minority Interest | 1.09 | 0.847 | 0 | ||
| Other Liabilities, Total | 264.375 | 254.265 | 97.109 | 109.432 | 217.2 |
| Total Equity | -49.296 | 266.153 | 493.492 | 1371.85 | 11893.7 |
| Common Stock | 166.764 | 193.296 | 232.304 | 246.31 | 246.3 |
| Retained Earnings (Accumulated Deficit) | -216.06 | 72.857 | 266.713 | 1130.32 | 11651.2 |
| Total Liabilities & Shareholders’ Equity | 374.713 | 652.986 | 797.647 | 2318.62 | 15830.8 |
| Total Common Shares Outstanding | 226.262 | 226.262 | 226.78 | 241.521 | 242.521 |
| Capital Lease Obligations | 54.127 | 78.031 | 153.7 | ||
| Treasury Stock - Common | -5.525 | -4.789 | -3.8 | ||
| Deferred Income Tax | 0.281 | 66.7 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 3536 | 8439.5 | 13551.4 | 15072.3 | 19466.1 |
| Cash and Short Term Investments | 892 | 914.9 | 2394.5 | 2074.3 | 6165 |
| Cash | 891.5 | 914.1 | 2392.7 | 1692.7 | 6164.1 |
| Short Term Investments | 0.5 | 0.8 | 1.8 | 381.6 | 0.9 |
| Total Receivables, Net | 2396 | 7052.6 | 10604.8 | 12382.1 | 12696.2 |
| Accounts Receivable - Trade, Net | 2395.1 | 7051.7 | 10603.9 | 12381.7 | 12695.8 |
| Total Inventory | 146.9 | 305.4 | 393.4 | 502.5 | 459.3 |
| Other Current Assets, Total | 101.1 | 166.6 | 158.7 | 113.4 | 145.6 |
| Total Assets | 4204.7 | 9148.8 | 14232.6 | 15830.8 | 20299.6 |
| Property/Plant/Equipment, Total - Net | 360.8 | 381.1 | 442.1 | 520.4 | 556.9 |
| Intangibles, Net | 165.2 | 164.1 | 162.9 | 202.4 | 216 |
| Other Long Term Assets, Total | 142.7 | 164.1 | 76.2 | 14.4 | 12.2 |
| Total Current Liabilities | 1311.1 | 3163.3 | 4902.6 | 3481.6 | 3854.5 |
| Accounts Payable | 106.2 | 262.7 | 258.9 | 160 | 123.7 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 18 | 13.9 | 19 | 129.9 | 30.6 |
| Other Current Liabilities, Total | 1186.9 | 2886.7 | 4624.7 | 3191.7 | 3700.2 |
| Total Liabilities | 1685.1 | 3666 | 5521.1 | 3937.1 | 4388.9 |
| Total Long Term Debt | 236.6 | 242.9 | 267.7 | 171.6 | 155.4 |
| Long Term Debt | 236.6 | 242.9 | 267.7 | 171.6 | 155.4 |
| Deferred Income Tax | 0 | 0 | 0 | 66.7 | 50.9 |
| Other Liabilities, Total | 137.4 | 259.8 | 350.8 | 217.2 | 328.1 |
| Total Equity | 2519.6 | 5482.8 | 8711.5 | 11893.7 | 15910.7 |
| Common Stock | 246.3 | 246.3 | 246.3 | 246.3 | 246.8 |
| Retained Earnings (Accumulated Deficit) | 2278.1 | 5240.3 | 8469 | 11651.2 | 15667.7 |
| Treasury Stock - Common | -4.8 | -3.8 | -3.8 | -3.8 | -3.8 |
| Total Liabilities & Shareholders’ Equity | 4204.7 | 9148.8 | 14232.6 | 15830.8 | 20299.6 |
| Total Common Shares Outstanding | 241.521 | 241.521 | 241.521 | 242.521 | 242.521 |
| Long Term Investments | 21.3 | 48.4 |
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -85.905 | -47.662 | -179.44 | -145.802 | 15046.4 |
| Cash From Operating Activities | -52.562 | -58.877 | -198.537 | -13.474 | 889.7 |
| Cash From Operating Activities | 10.529 | 21.984 | 33.896 | 38.744 | 75.2 |
| Non-Cash Items | 29.416 | 7.943 | 31.109 | 188.487 | -32.6 |
| Cash Taxes Paid | 0.045 | 0.304 | -0.122 | -0.378 | 3457.9 |
| Cash Interest Paid | 0.729 | 1.769 | 2.044 | 3.628 | 12.2 |
| Changes in Working Capital | -6.602 | -41.142 | -84.102 | -94.903 | -14199.3 |
| Cash From Investing Activities | -52.549 | -66.452 | -77.115 | -144.848 | -566.1 |
| Capital Expenditures | -57.742 | -67.157 | -71.08 | -85.446 | -154 |
| Other Investing Cash Flow Items, Total | 5.193 | 0.705 | -6.035 | -59.402 | -412.1 |
| Cash From Financing Activities | -1.643 | 365.177 | 383.29 | 894.725 | 94.2 |
| Issuance (Retirement) of Stock, Net | 0 | 361.725 | 375.351 | 753.007 | 160.9 |
| Issuance (Retirement) of Debt, Net | -1.643 | 3.452 | 7.939 | 141.718 | -66.7 |
| Foreign Exchange Effects | -24.82 | -0.459 | 0.016 | -45.343 | 64.7 |
| Net Change in Cash | -131.574 | 239.389 | 107.654 | 691.06 | 482.5 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1642.3 | 5665.1 | 10332.5 | 15046.4 | 5018.1 |
| Cash From Operating Activities | -311.3 | -411.6 | 1089.2 | 889.7 | 4050.2 |
| Cash From Operating Activities | 13 | 29.4 | 49.2 | 75.2 | 27.6 |
| Non-Cash Items | -37.2 | 69.3 | -15.6 | -32.6 | -197 |
| Cash Taxes Paid | 0.1 | 0.3 | 1 | 3457.9 | 1290 |
| Cash Interest Paid | 1.8 | 3.9 | 6.1 | 12.2 | 6.4 |
| Changes in Working Capital | -1929.4 | -6175.4 | -9276.9 | -14199.3 | -798.5 |
| Cash From Investing Activities | -28.3 | -58.1 | -99.2 | -566.1 | 287.4 |
| Capital Expenditures | -29.2 | -59.3 | -100.6 | -154 | -60.8 |
| Other Investing Cash Flow Items, Total | 0.9 | 1.2 | 1.4 | -412.1 | 348.2 |
| Cash From Financing Activities | -4.5 | 148.4 | 143.1 | 94.2 | 80.3 |
| Issuance (Retirement) of Debt, Net | -4.5 | -12.5 | -17.8 | -66.7 | -30.2 |
| Foreign Exchange Effects | 25.4 | 25.2 | 49.4 | 64.7 | 53.5 |
| Net Change in Cash | -318.7 | -296.1 | 1182.5 | 482.5 | 4471.4 |
| Issuance (Retirement) of Stock, Net | 160.9 | 160.9 | 160.9 | 110.5 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| AT Impf GmbH | Corporation | 43.7253 | 106114901 | -8295437 | 2021-12-31 | |
| Medine GmbH | Corporation | 17.1027 | 41505853 | -157577 | 2021-12-31 | |
| Baillie Gifford & Co. | Investment Advisor | 3.1803 | 7718123 | 473051 | 2022-12-31 | LOW |
| Temasek Holdings Pte. Ltd. | Sovereign Wealth Fund | 1.804 | 4378022 | 3840388 | 2022-09-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 1.7283 | 4194388 | -6910 | 2022-09-30 | LOW |
| Flossbach von Storch AG | Investment Advisor | 1.3864 | 3364564 | 299414 | 2022-09-30 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 0.9184 | 2228913 | 1487687 | 2022-09-30 | LOW |
| Huber (Christoph M.D.) | Individual Investor | 0.825 | 2002040 | -200000 | 2021-12-31 | |
| Jeggle (Helmut) | Individual Investor | 0.7936 | 1925967 | -300000 | 2021-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.7598 | 1843891 | 329510 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 0.6695 | 1624662 | 880179 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6069 | 1472867 | -98301 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.5177 | 1256309 | -591626 | 2022-09-30 | LOW |
| Fosun International Ltd | Investment Advisor | 0.3138 | 761538 | -242102 | 2022-09-30 | LOW |
| ACATIS Investment Kapitalverwaltungsgesellschaft GmbH | Investment Advisor | 0.303 | 735400 | -1200 | 2022-11-30 | LOW |
| Marett (Sean) | Individual Investor | 0.2909 | 705936 | -280000 | 2021-12-31 | |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.2481 | 602103 | -4086 | 2022-09-30 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.2411 | 585125 | -40964 | 2022-09-30 | LOW |
| Baillie Gifford Overseas Ltd. | Investment Advisor | 0.227 | 550905 | 15695 | 2022-11-30 | HIGH |
| Poetting (Sierk) | Individual Investor | 0.2168 | 526062 | -128325 | 2021-12-31 |
Traders
Active clients monthly
Monthly investing volume
Withdrawn each month
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Founded in 2008, BioNTech is an innovative biotechnology company from Germany, specialising in the research, development and producing of active individualised immunotherapies. The company adheres to a patient-specific approach to treatment of serious diseases, such as cancer.
BioNTech shares a vision that every patient’s tumour is unique. It means that each patient’s treatment should be individualised. To implement the scientists’ ideas into practice, BioNTech has developed pioneering therapeutics for cancer and other rare and infectious diseases.
Headquartered in Mainz, Germany, the company is aimed at becoming the world’s leading biotechnology company for individialised cancer treatment. By 2020, BioNTech had more than 440 patients treated across 17 tumour types. The company has more than 1,300 employees and seven pharmaceutical partners.
In August 2018, the company partnered with the US pharmaceutical giant Pfizer Inc to develop mRNA-based vaccines for preventing influenza. In September 2019, BioNTech started working on the development of tuberculosis and HIV programmes and preclinical vaccine and immunotherapy candidates for the prevention of tuberculosis and HIV infections under an agreement with the Bill & Melinda Gates Foundation.
BioNTech stock floated on the NASDAQ stock exchange through a $150m initial public offering (IPO) in October 2019. Since then the BNTX stock quote has been traded on the US market.
In November 2020, BioNTech and Pfizer triggered the strongest wave of optimism on the stock market after they announced that their Covid-19 vaccine showed 90 per cent effectiveness during the phase-three clinical trials. The BioNTech share price soared 14 per cent the day after the announcement.
In 2019, BioNTech reported total revenues of about €109m. According to the estimates from Morgan Stanley, BioNTech and Pfizer can make around $13bn from vaccine sales, getting $6.5bn each if these estimates are correct.
Looking closely at the BioNTech stock price chart in 2020, we can see that BNTX stock has been trading in a range of $18.60-$115. Since the large sell-off in March 2020, the BioNTech SE (BNTX) stock quote grew from $28.55 on March 12, 2020, to $112.76 on November 10, 2020, which is a growth of 294 per cent.
Follow the BioNTech share price live on our interactive share price chart and build your own forecast for the famous German biotechnology company. Follow the latest BioNTech share news and spot the best levels to open profitable CFD trades at Capital.com.
| Industry: | Bio Therapeutic Drugs |
An der Goldgrube 12
MAINZ
RHEINLAND-PFALZ 55131
DE
FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023Invest in BioNTech shares, other major stocks, indices, forex, commodities and cryptocurrencies with CFDs at Capital.com’s award-winning platform. No commission. FCA and CySEC regulated. Available on web and mobile. AI technology.
Learn more about Biontech SE
Join the 480.000+ traders worldwide that chose to trade with Capital.com
